After 16 years heading up research and development at Dendreon, David Urdal is due to step down from the company at the end of this year. During his tenure he oversaw the tumultuous development and approval of the first active cancer immunotherapy — sipuleucel-T (Provenge) — for metastatic prostate cancer, which finally made it to market in 2010. Before joining Dendreon, Urdal spent 13 years at Immunex helping, among other things, to launch the first therapeutic fusion protein, etanercept (Enbrel). As he prepares to pack up his office after three decades in industry, he spoke with Asher Mullard about his latest success and the changing biotechnology sector.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
David Urdal. Nat Rev Drug Discov 10, 806–807 (2011). https://doi.org/10.1038/nrd3584
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3584
